Tarsus Pharmaceuticals, Inc.
NASDAQ:TARSBiotechnology
+$0.29 today
- Market cap
- $3.74B
- Beta
- 0.51
- P/E (TTM)
- -55.9
- EPS (TTM)
- -$1.12
Volume 0.45M
Average 0.61M
TARS Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Tarsus Pharmaceuticals, Inc.NASDAQ: TARS
Net Receivables · Q3 FY2026 · quarter ended Sep 2026
Net receivables rises 37.4% from a year ago
Net receivables stood at $102.11M at the end of Q3 FY2026, up 37.4% from a year earlier and up 3.9% from the prior quarter. Over 3 fiscal years it compounded at +189.7% a year.
Context
- Net receivables amounted to 20.2% of total assets at the end of Q3 FY2026, up 6.3 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +37.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 87.11M USD
- Year-over-year change
- +81.3%
- 4-year CAGR
- +454.7%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 87.11M | +81.3% |
| FY2024 | 2024-12-31 | 48.06M | +171.3% |
| FY2023 | 2023-12-31 | 17.71M | +394.5% |
| FY2022 | 2022-12-31 | 3.58M | +3793.5% |
| FY2021 | 2021-12-31 | 92K | — |
Net Receivables vs competitors
How TARS compares with its peers on the latest reported figures
- TARS's Sep 2026 net receivables of $102.11M is the 2nd highest of the 6 companies compared; the peer median is $7.81M.
- Its year-over-year change of +37.4% is the 3rd highest of 5, against a peer median of +34.6%.
- Net receivables amounts to 20.2% of total assets for TARS, versus a peer median of 20.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $155.16M | +45.4% | +158.6% | 31.8% | |
| Sep 2026 | $102.11M | +37.4% | +189.7% | 20.2% | |
| Mar 2026 | $101.26M | +31.0% | +158.9% | 24.1% | |
| Mar 2026 | $7.81M | +38.2% | +123.0% | 20.1% | |
| Mar 2026 | $1.07M | -72.5% | -37.1% | 1.8% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding TARS) | $7.81M | +34.6% | +140.8% | 20.1% | |
Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 171.33M | 71.66M | 224.95M | 94.82M | 183.64M |
| Short-term Investments | 483K | 145.37M | 2.5M | 196.56M | 233.63M |
| Net Receivables | 92K | 3.58M | 17.71M | 48.06M | 87.11M |
| Inventory | 0 | 0 | 3.11M | 2.62M | 4.37M |
| Other Current Assets | 0 | 0 | 0 | 0 | 560K |
| Total Current Assets | 175.95M | 225.38M | 256.13M | 356.71M | 522.78M |
| Property, Plant & Equipment (Net) | 1.83M | 1.53M | 3.35M | 2.87M | 21.75M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 3.87M | 8.33M | 7.37M |
| Long-term Investments | 663K | 371K | 631K | 3M | 3.87M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 463K | 585K | 1.51M | 6.09M | 6.4M |
| Total Non-current Assets | 2.96M | 2.49M | 9.36M | 20.29M | 39.38M |
| Total Assets | 178.91M | 227.86M | 265.49M | 376.99M | 562.16M |
| Account Payables | 2.86M | 5.5M | 17.77M | 27.74M | 16.39M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 55K | 14K | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 56K | 0 | 0 | 0 | 117.5M |
| Total Current Liabilities | 11.48M | 15.43M | 36.94M | 80.61M | 135.7M |
| Long-term Debt | 0 | 19.43M | 29.82M | 71.85M | 83.04M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 114K | 48K | 1.75M | 0 | (10.6M) |
| Total Non-current Liabilities | 699K | 19.53M | 31.57M | 71.85M | 83.04M |
| Total Liabilities | 12.18M | 34.96M | 68.5M | 152.46M | 218.73M |
| Common Stock | 4K | 5K | 5K | 6K | 6K |
| Retained Earnings | (46.67M) | (108.76M) | (244.66M) | (360.21M) | (426.63M) |
| Accumulated OCI | 0 | (74K) | (2K) | 179K | 381K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 166.73M | 192.9M | 196.99M | 224.53M | 343.43M |
| Total Debt | 1.89M | 20.21M | 30.22M | 72.45M | 93.64M |
| Net Debt | (169.44M) | (51.45M) | (194.73M) | (22.37M) | (90.01M) |
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
Intrinsic Alpha fair value
Locked
Current Price
$75.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.